Angiogenesis inhibitors rechallenge in patients with advanced non-small-cell lung cancer: a pooled analysis of randomized controlled trials

PURPOSE: Data on the role of angiogenesis inhibitors (AIs) rechallenge in the treatment of advanced non-small-cell lung cancer (NSCLC) patients who previously received bevacizumab remain limited. We aim to investigate the efficacy of AIs in the treatment of advanced NSCLC in this setting. METHODS: S...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Lingdi, Li, Wei, Zhang, Huiying, Hou, Nan, Guo, Lanwei, Gao, Quanli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599042/
https://www.ncbi.nlm.nih.gov/pubmed/26491352
http://dx.doi.org/10.2147/OTT.S88102

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599042/
https://www.ncbi.nlm.nih.gov/pubmed/26491352
http://dx.doi.org/10.2147/OTT.S88102

Ejemplares similares